What does FOURIER stand for?

Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk. It is a backronym, as is common in cardiology trials.

How is evolocumab given in the FOURIER trial?

Patients self-administered subcutaneous injections using either a 140 mg autoinjector every two weeks or a 420 mg SureClick device once monthly. Both schedules produced equivalent LDL reductions.

Did FOURIER show a mortality benefit?

No. Cardiovascular death rates were nearly identical between groups at 2.2 years. However, the longer-term FOURIER-OLE extension study reported a significant 23% reduction in CV death after approximately 7 years of cumulative follow-up.

How low did LDL cholesterol go in the evolocumab group?

The median LDL at 48 weeks was 30 mg/dL, down from a baseline of 92 mg/dL. About 42% of treated patients reached LDL levels below 25 mg/dL.

Is it safe to have an LDL that low?

In FOURIER, patients with very low LDL (<20 mg/dL) showed no excess adverse events compared to those with higher levels. The EBBINGHAUS neurocognitive sub-study found no cognitive impairment at these levels over 19 months of follow-up.

Were women and minorities adequately represented?

The trial enrolled 25% women and was 85% white. These proportions limit the ability to draw firm conclusions about efficacy and safety in underrepresented groups, though subgroup analyses did not suggest differential treatment effects by sex.

How does FOURIER compare to ODYSSEY OUTCOMES?

ODYSSEY OUTCOMES tested alirocumab (Praluent) in post-acute coronary syndrome patients and found a similar 15% MACE reduction. Unlike FOURIER, ODYSSEY OUTCOMES showed a signal toward reduced all-cause mortality, possibly because it enrolled higher-risk patients closer to their index event.

Do current guidelines recommend PCSK9 inhibitors based on FOURIER?

Yes. The 2018 AHA/ACC cholesterol guidelines cite FOURIER as Level A evidence supporting PCSK9 inhibitor use in ASCVD patients with LDL above 70 mg/dL despite maximally tolerated statins, particularly with additional high-risk features.

What is the biggest barrier to prescribing evolocumab today?

Cost and insurance access. Despite list price reductions since launch, prior authorization requirements remain common. Many eligible patients never receive the drug due to administrative burden and copay concerns.

Did patients in FOURIER take ezetimibe too?

About 5% of patients were on ezetimibe at baseline. The trial did not require it. Current guidelines recommend ezetimibe as an intermediate step before PCSK9 inhibitors, meaning today's eligible patients may have lower baseline LDL than those in FOURIER.

FOURIER Trial: A Plain-English Overview of What It Established

Q: Were women and minorities adequately represented?

The trial enrolled 25% women and was 85% white. These proportions limit the ability to draw firm conclusions about efficacy and safety in underrepresented groups, though subgroup analyses did not suggest differential treatment effects by sex.

Q: How does FOURIER compare to ODYSSEY OUTCOMES?

ODYSSEY OUTCOMES tested alirocumab (Praluent) in post-acute coronary syndrome patients and found a similar 15% MACE reduction. Unlike FOURIER, ODYSSEY OUTCOMES showed a signal toward reduced all-cause mortality, possibly because it enrolled higher-risk patients closer to their index event.

Q: Do current guidelines recommend PCSK9 inhibitors based on FOURIER?

Yes. The 2018 AHA/ACC cholesterol guidelines cite FOURIER as Level A evidence supporting PCSK9 inhibitor use in ASCVD patients with LDL above 70 mg/dL despite maximally tolerated statins, particularly with additional high-risk features.

Q: What is the biggest barrier to prescribing evolocumab today?

Cost and insurance access. Despite list price reductions since launch, prior authorization requirements remain common. Many eligible patients never receive the drug due to administrative burden and copay concerns.

Q: Did patients in FOURIER take ezetimibe too?

About 5% of patients were on ezetimibe at baseline. The trial did not require it. Current guidelines recommend ezetimibe as an intermediate step before PCSK9 inhibitors, meaning today's eligible patients may have lower baseline LDL than those in FOURIER.

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

At a glance

| Parameter | Detail | |---|---| | N | 27,564 | | Intervention | Evolocumab 140 mg every 2 weeks or 420 mg monthly (subcutaneous) | | Comparator | Matching placebo | | Background therapy | Moderate- or high-intensity statin (required) | | Median follow-up | 2.2 years | | Primary endpoint | Composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization | | Key result | 15% relative risk reduction in primary endpoint (HR 0.85; 95% CI 0.79, 0.92; p <0.001) |

The question FOURIER was designed to answer

By 2012, when enrollment began, clinicians already knew that PCSK9 inhibitors could slash LDL cholesterol by 50 to 60% on top of statins. Phase II and III lipid-lowering studies had demonstrated that consistently. But lowering a lab number is not the same as preventing heart attacks. The statin era had taught the field that lesson the hard way: some drugs lower LDL without reducing events (torcetrapib being the most famous failure). FOURIER was built to answer a single, high-stakes question: does adding evolocumab to optimized statin therapy actually prevent cardiovascular events in patients who already have atherosclerotic disease?

The trial was sponsored by Amgen and conducted across 1,242 sites in 49 countries. It was, at the time, one of the largest cardiovascular outcomes trials ever run for a non-statin lipid drug.

Who got enrolled (and who did not)

Participants were between 40 and 85 years old with clinically evident atherosclerotic cardiovascular disease (ASCVD), defined as prior myocardial infarction, prior non-hemorrhagic stroke, or symptomatic peripheral artery disease. Everyone had to be on a stable statin dose (atorvastatin 20 mg or equivalent as a minimum) with an LDL cholesterol of at least 70 mg/dL, or a non-HDL cholesterol of at least 100 mg/dL.

Key exclusions: uncontrolled diabetes (HbA1c >10%), recent acute coronary syndrome within four weeks of randomization, planned cardiac surgery, NYHA class III/IV heart failure, and severe renal impairment (eGFR <20 mL/min). These exclusions matter because they limit how far the results can be generalized. A patient with very recent MI or advanced heart failure was not represented in FOURIER.

The enrolled population skewed male (75%), with a median age of 63. About 81% had a history of MI, 19% had PAD, and 19% had prior stroke (categories overlapped). Median baseline LDL was 92 mg/dL, despite statin use, confirming substantial residual cholesterol burden in this population.

What the treatment actually looked like

Patients chose between two dosing schedules: 140 mg subcutaneous injection every two weeks or 420 mg once monthly. Both regimens produce similar average LDL reductions. The choice was a pragmatic design element meant to improve adherence; in clinical practice, the same flexibility exists for Repatha prescribing.

LDL cholesterol at 48 weeks dropped to a median of 30 mg/dL in the evolocumab group (from a baseline of 92), compared to 93 mg/dL in the placebo group. That is a 59% reduction. Roughly 42% of evolocumab-treated patients achieved LDL <25 mg/dL, a range that had almost no prior safety data at scale.

What was measured and how

The trial used a two-tier endpoint framework that separates "softer" events from the hardest clinical outcomes:

Primary composite (5-component): cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization. This broader net captures a wider range of events and provides more statistical power.

Key secondary composite (3-component): cardiovascular death, myocardial infarction, or stroke. This is the "harder" composite, limited to events that are less susceptible to physician decision-making and coding variability.

Separating endpoints this way lets readers evaluate whether the drug prevents events that are unambiguously serious (MI, stroke, death) or whether the signal is driven by revascularization procedures and unstable angina hospitalizations, which involve more clinical judgment. FOURIER showed a benefit in both composites, which strengthens the finding.

The trial was event-driven, requiring at least 1,630 primary endpoint events before final analysis. It was powered for 90% probability of detecting a 15% risk reduction with a two-sided alpha of 0.05.

Results in detail

Primary endpoint

| Outcome | Evolocumab | Placebo | Hazard Ratio (95% CI) | p-value | |---|---|---|---|---| | Primary composite (5-component) | 9.8% | 11.3% | 0.85 (0.79, 0.92) | <0.001 | | Key secondary composite (3-component) | 5.9% | 7.4% | 0.80 (0.73, 0.88) | <0.001 |

The primary endpoint hit statistical significance with a 15% relative risk reduction. The harder 3-component secondary endpoint showed a 20% relative risk reduction, which is noteworthy. It suggests the benefit was not being inflated by softer events like revascularization decisions.

Individual components

| Component | Evolocumab (%) | Placebo (%) | HR (95% CI) | |---|---|---|---| | Cardiovascular death | 1.8 | 1.7 | 1.05 (0.88, 1.25) | | Myocardial infarction | 3.4 | 4.6 | 0.73 (0.65, 0.82) | | Stroke | 1.5 | 1.9 | 0.79 (0.66, 0.95) | | Coronary revascularization | 5.5 | 6.6 | 0.83 (0.75, 0.93) | | Unstable angina hospitalization | 0.6 | 0.7 | 0.87 (0.67, 1.13) |

The standout finding: MI dropped by 27% and stroke by 21%. Cardiovascular death did not budge. That zero effect on CV death became the single most debated aspect of FOURIER.

Time-dependent benefit

A pre-specified landmark analysis split outcomes into the first 12 months versus beyond 12 months. In the first year, the primary composite showed a non-significant 12% reduction (HR 0.88). After year one, the reduction grew to 19% (HR 0.81). For the harder 3-component secondary, the beyond-12-month reduction reached 25%. This pattern suggests that PCSK9 inhibitor benefit accrues over time, consistent with how atherosclerotic plaque stabilization works biologically. It also raises a question about whether 2.2 years of median follow-up was simply too short to see a mortality signal.

Why cardiovascular death did not fall

This is the central criticism of FOURIER and deserves honest treatment. Several explanations have been proposed, and they are not mutually exclusive:

Short follow-up. Statin mega-trials like 4S and HPS ran for 5+ years before CV death separation emerged. FOURIER's 2.2-year median may have been insufficient. The open-label extension (FOURIER-OLE) followed patients for a median of 5 additional years and reported a 23% reduction in CV death (HR 0.77; 95% CI 0.60, 0.99), suggesting that longer exposure does translate into mortality benefit.

Low event rate for CV death. With rates of only 1.7 to 1.8%, the trial was underpowered for this specific endpoint. You need more events or more time to detect a difference.

Background statin therapy. All patients were already on statins, which had already captured some of the mortality benefit of LDL lowering. The incremental gain from further lowering may take longer to emerge.

Safety signals and non-signals

Injection-site reactions were more common with evolocumab (2.1% vs. 1.6%). Serious adverse events, including new-onset diabetes, neurocognitive events, and musculoskeletal complaints, were balanced between groups. The prespecified neurocognitive sub-study (EBBINGHAUS) found no difference in cognitive function at a median of 19 months despite LDL levels well below 25 mg/dL. This was clinically important because theoretical concerns about very low LDL and brain cholesterol metabolism had delayed regulatory enthusiasm for PCSK9 inhibitors.

Anti-drug antibodies developed in 0.3% of evolocumab patients. None were neutralizing. This is a class advantage of fully human monoclonal antibodies compared to humanized constructs.

Limitations the investigators acknowledged

Median follow-up of 2.2 years was shorter than many statin trials and likely insufficient for mortality endpoints.
Open-label run-in period of 12 to 14 weeks: patients who did not tolerate injections or discontinued early were excluded, potentially inflating adherence rates beyond real-world expectations.
Population homogeneity: 85% white, 75% male. Applicability to women, Black patients, and Asian populations requires separate data.
Industry sponsorship: Amgen funded the trial and participated in data collection. An independent academic executive committee led the analysis, but the financial relationship should be noted.
Statin optimization was not verified: while all patients were on statins at entry, approximately 30% were on moderate-intensity rather than high-intensity therapy. Whether maximizing statin dose first would have narrowed the benefit of adding evolocumab is unknown.

What FOURIER changed in clinical practice

The 2018 AHA/ACC cholesterol guidelines incorporated FOURIER as Level A evidence supporting PCSK9 inhibitor use in patients with ASCVD whose LDL remains above 70 mg/dL on maximally tolerated statin therapy (with or without ezetimibe). The 2022 update reinforced this. FOURIER, together with the ODYSSEY OUTCOMES trial for alirocumab, established that the "lower is better" LDL hypothesis extends well below 70 mg/dL.

The practical barrier remains cost. At launch, Repatha was priced at roughly $14,000/year. Amgen has since reduced the list price and offered copay assistance programs. Prior authorization requirements from insurers remain common, which limits uptake to a fraction of eligible patients. The cost-effectiveness debate, more than the clinical evidence, continues to shape real-world prescribing patterns.

Bottom line

FOURIER proved that adding a PCSK9 inhibitor to statin therapy reduces non-fatal MI and stroke in patients with established ASCVD. It did not prove a CV death benefit in 2.2 years, though longer-term follow-up data now suggest one exists. The safety profile was clean, including at very low LDL levels. For patients who have had a heart attack or stroke and whose LDL stays above goal on a statin, this trial provides the evidence base for considering evolocumab as a next step.

Frequently asked questions

›

References

Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-1722. PubMed
Giugliano RP, Pedersen TR, Saver JL, et al. Stroke Prevention With the PCSK9 Inhibitor Evolocumab Added to Statin Therapy in Patients With Prior Stroke or TIA. Circulation. 2017;136(Suppl 1). PubMed
O'Donoghue ML, Giugliano RP, Wiviott SD, et al. Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease (FOURIER-OLE). Circulation. 2022;146(15):1109-1119. PubMed
Giugliano RP, Mach F, Zavitz K, et al. Cognitive Function in a Randomized Trial of Evolocumab (EBBINGHAUS). N Engl J Med. 2017;377(7):633-643. PubMed
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC Guideline on the Management of Blood Cholesterol. J Am Coll Cardiol. 2019;73(24):e285-e350. PubMed
Repatha (evolocumab) Prescribing Information. Amgen Inc. FDA Label